Patent · US Active

CTLA-4 variants

US9884902B2 · kind B2 · utility

4Cited by

2References

15Claims

0Family size

Assignee

MedImmune Limited · US

Inventors

Ralph Minter · Cambridge, GB
Julie Ann DOUTHWAITE · Cambridge, GB
Jacques Moisan · North Potomac, US
Michael Bowen · Rockville, US
Steven Rust · Cambridge, GB
Cyril Privezentzev · Cambridge, GB

Key dates

Filing date	Mar 11, 2013
Grant date	Feb 6, 2018
Priority date	—
Expiry date	Dec 28, 2033

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Variants of cytotoxic T-lymphocyte antigen 4 (CTLA-4) with high affinity, potency and stability. Formulations of CTLA-4 variants at high concentration for subcutaneous or intravenous administration, e.g. at monthly or less frequent dosage intervals. Use of CTLA-4 variants for treating rheumatoid arthritis and other inflammatory disorders. Fusion of CTLA-4 with IgG Fc having improved stability and longer in vivo half-life.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.